Additionally, anti-PD-1/PD-L1 immunotherapy (pembrolizumab, atezolizumab, or cemiplimab) is the preferred approach for advanced NSCLC patients with high PD-L1 expression (≥50%) and no actionable molecular biomarkers [9]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.